Chemical modification of transcripts with 5' caps occurs in all organisms. Here we report a 8 systems-level mass spectrometry-based technique, CapQuant, for quantitative analysis of the 9 cap epitranscriptome in any organism. The method was piloted with 21 canonical caps -10 m 7 GpppN, m 7 GpppNm, GpppN, GpppNm, and m 2,2,7 GpppG -and 5 "metabolite" caps -NAD, 11 FAD, UDP-Glc, UDP-GlcNAc, and dpCoA. Applying CapQuant to RNA from purified dengue 12 virus, Escherichia coli, yeast, mice, and humans, we discovered four new cap structures in 13 humans and mice (FAD, UDP-Glc, UDP-GlcNAc, and m 7 Gpppm 6 A), cell-and tissue-specific 14 variations in cap methylation, and surprisingly high proportions of caps lacking 2'-O-methylation, 15 such as m 7 Gpppm 6 A in mammals and m 7 GpppA in dengue virus, and we did not detect cap 16 m 1 A/m 1 Am in humans. CapQuant accurately captured the preference for purine nucleotides at 17 eukaryotic transcription start sites and the correlation between metabolite levels and metabolite 18 caps. The mystery around cap m 1 A/m 1 Am analysis remains unresolved. 19 20 21 cap structure involves -phosphate methylation of unprocessed 5'-triphosphate (mPPPN) on 1 small RNAs such as mammalian U6 and 7SK, mouse B2, and plant U3 RNAs (7). 2 A variety of non-canonical caps involving nucleotide metabolites (Figure 1A) have also recently 3 been described (8,9). For example, nicotinamide adenine dinucleotide (NAD) and coenzyme A 4 (CoA) were found as cap-like structures in bacterial small RNAs (10) and the NAD cap was also 5 found in yeast and human mRNA and non-coding RNAs (11). Julius and Yuzenkova expanded 6 the potential repertoire of caps by demonstrating that a variety of nucleotide metabolites could 7 initiate transcription by bacterial RNA polymerase (RNA Pol) in vitro, including flavin adenine 8 dinucleotide (FAD), uridine diphosphate glucose (UDP-Glc), and uridine diphosphate N-9 acetylglucosamine (UDP-GlcNAc) (9). They also showed that capping with NAD and UDP 10 analogs by bacterial RNA Pol is promoter-specific and stimulates promoter escape (9), 11 suggesting a role for metabolite caps in regulating gene expression. For example, the NAD cap 12 has been shown to influence RNA stability and turnover, and is a substrate for decapping 13 enzymes (11). However, the lack of sensitive and specific analytical methods has hindered the 14 systematic study of the cap landscape dynamics in cells. 15
INTRODUCTION 1 2
Nearly all forms of RNA are post-transcriptionally modified on the nucleobases or ribose (1) , 3 including the 5'-terminal "caps" on messenger (mRNA) and other RNAs (2) . The canonical cap 4 on most eukaryotic and viral mRNAs is comprised of N 7 -methylguanosine (m 7 G) linked to the 5 first nucleotide of the RNA by a reverse 5'-5' triphosphate bridge (Figure 1A) (2) . This m 7 GpppX 6 cap in its various forms (2) is absent in bacterial and archaeal transcripts. In many lower 7 eukaryotes, including yeast, mRNAs contain mainly m 7 GpppN (cap 0), whereas in higher 8 eukaryotes, the 5' penultimate and antepenultimate nucleotides can be 2'-O-methylated to 9 different extents to generate m 7 GpppNm (cap 1) and m 7 GpppNmpNm (cap 2) structures (2) . 10
The m 7 GpppX cap has several important biological functions, such as protecting mRNA from 11 degradation by 5'-exoribonucleases, directing pre-mRNA splicing and nuclear mRNA export, 12 facilitating recognition by eukaryotic translation initiation factor 4E, and regulating various 13 aspects of mRNA fate and function, including mRNA stability and mRNA translation (2) . In 14 addition, the ribose 2'-O methylation (Nm) at the 5' penultimate nucleotide is thought to be a 15 molecular signature that discriminates self and non-self mRNA, and thus functions in antiviral 16 defense (3). 17
The family of eukaryotic RNA caps has recently expanded to include a variety of GpppX 18 variants and non-canonical structures, such as the non-methylated guanosine cap (GpppN) in 19 insect oocyte mRNA (4) . Building on the m 7 GpppAm motif, Moss and colleagues showed that 20 up to 30% of caps in animal and viral mRNAs are also methylated at N 6 of Am (m 6 Am) (5) . 21
Multiple methylations also occur on the cap 5'-G, such as di-and tri-methylguanosine caps (e.g., 22 m 2,2,7 GpppN) in viral RNAs (6) and a subset of RNAP II-transcribed cellular RNAs, including 23 small nuclear and nucleolar RNAs, and telomerase RNA (7) . Perhaps the simplest methylated 24 and the caps purified by ion-pairing HPLC, with cap fractions concentrated and cleaned up by 1 Speed-vac, as described in the HPLC section below. All purified synthetic cap dinucleotides 2 were >99% or >98% pure based on HPLC and were characterized by high-resolution mass 3 spectrometry (HRMS) ( Supplementary Table S2 ) and MS/MS analyses (Supplementary 4 Figure S1 ). The synthesis of RNA oligo containing a mixture of m 7 Gpppm 1 A and m 7 Gpppm 1 Am 5 in the 5' cap and the release and purification of m 7 Gpppm 1 A and m 7 Gpppm 1 Am were conducted 6 in the same fashion. The purified m 7 Gpppm 1 A and m 7 Gpppm 1 Am were >98% and >99% pure 7 respectively based on HPLC, with their identity confirmed by MS/MS analysis (Supplementary 8 Figure S1 ) and successful detection of m 1 A and m 1 Am, but not m 6 A and m 6 Am, respectively by 9 Figure S2) using the same method as the LC-MS/MS method 10 described below for Dimroth rearrangement analysis following hydrolysis into nucleosides by 11 RNA 5' pyrophosphohydrolase (RppH, NEB) and shrimp alkaline phosphatase (SAP, NEB). The 12 concentrations of the caps, m 7 Gpppm 1 A and m 7 Gpppm 1 Am were measured by their UV 13 absorbance at 260 nm. The isotopic purity of the caps was found to be better than 99.6% (data 14 not shown) based on LC-MS/MS analyses. 15 16 m 1 A, m 6 A, m 1 Am and m 6 Am nucleoside standards 17 m 1 A, m 6 A and m 6 Am were purchased from Berry and Associates (Dexter, MI USA). m 1 Am was 18 synthesized by reaction of methyl iodide (0.3 mL) with 2'-O-methyladenosine (100 mg) in 19 anhydrous DMF (2.0 mL) in a closed flask with stirring at ambient temperature for 18 h. The 20 reaction mixture was evaporated under vacuum and triturated with diethyl ether to afford a white 21 solid (120 mg). A portion of this crude solid (40 mg) was dissolved in 3.0 mL of methanol and 22 treated with aqueous ammonia (3.0 mL) by stirring at ambient temperature for 10 min. Following 23 evaporation of solvent under vacuum, the mixture was resolved by chromatography on 200-400 24 mesh silica gel eluted with 15-20% methanol in dichloromethane with 1% aqueous ammonia to 25 afford m 1 Am (25 mg, 59%) as a white solid. The product was characterized by 1 H and 13 C NMR 26 (Supplementary Figure S3 ) and HRMS: 1 H NMR (DMSO-D6, 400 MHz) δ 8. 18 (s, 1H) , 8.09 (s, 1 1H), 7.03 (bs, H,), 5.87 (d, J = 6.00 Hz, 1H), 5.25 (d, J = 5.24 Hz, 1H), 5.14 (t, J = 5.54 Hz, 1H), 2 4.29 (m, 1H), 4.25 (m, 1H) , 3.95 (q, J = 10.68 Hz, 1H), 3.65 (m, 1H), 3.56 (m, 1H), 3.43 (s, 3H), 3 3.31 (s, 3H); 13 C (DMSO-D6, 100 MHz) δ 154. 8, 149.1, 141.9, 138.1, 123.1, 86.7, 85.9, 83.4, 4 69.1, 61.8, 58.0, 35.1; HRMS (ESI, m/z) when the O.D. reached 0.5. After 1 h treatment, the cells were collected by centrifugation 10 (4,500 g at 4 o C) and washed twice with ice-cold PBS. 11
LC-MS/MS (Supplementary

12
RNA extraction 13
The total RNA from CCRF-SB pellets was directly extracted with TRIzol reagent (Life 14 Technologies), according to the manufacturer's protocol. For mice, the liver and kidney tissues 15
were ground under liquid nitrogen into fine powders in a mortar, the total RNA of which were 16 then extracted with TRIzol reagent as described earlier. For yeast, total RNA was extracted with 17 a MasterPure Yeast RNA Purification kit (Epicentre) following the manufacturer's protocol. For E. 18 coli, lysis was performed with lysozyme, before total RNA was extracted with TRIzol reagent as 19 described earlier. Briefly, 0.8 ml of TE buffer (pH 8.0) containing 80 mg lysozyme (Fluka) was 20 added to approximately 3.7  10 10 E. coli DH5 cells and the mixture was incubated for 2 h at 21 room temperature. To the mixture was then added 0.6 ml of TE buffer (pH 8.0) containing 60 mg 22 lysozyme, followed by incubation for another 2 h at room temperature. Total RNA was 23 subsequently extracted with TRIzol following the manufacturer's instructions. The genomic RNA 24 from purified dengue virions was extracted with TRIzol and purified by size-exclusion 25 chromatography as described previously (23, 25) . The poly(A)-tailed RNA in human CCRF-SB 1 cells was isolated from the total RNA using a Fasttrack MAG Maxi mRNA isolation kit (Life 2 Technologies), whereas the poly(A)-tailed RNA in yeast cells and mouse tissues was isolated 3 from the total RNA using a Dynabeads mRNA Purification kit (Life Technologies) following the 4 manufacturer's protocols. rRNA depletion of the poly(A)-tailed RNA isolated from yeast cells and 5 mouse tissues was subsequently performed using a GeneRead rRNA Depletion kit (Qiagen), 6
according to the manufacturer's protocol. The rRNA-depleted RNA was then cleaned up using a 7
RNeasy MinElute Cleanup kit (Qiagen), following the manufacturer's protocol. No rRNA 8 depletion and subsequent clean-up was performed for the poly(A)-tailed RNA isolated from 9
human CCRF-SB cells because there was no sign of significant rRNA contamination 10 (Supplementary Figure S4 ). All RNA samples were stored at -80 °C before use. The quality of 11 the total RNA (Supplementary Figure S5) , poly(A)-tailed RNA (Supplementary Figure S4) , 12
and purified DENV-2 RNA genome (Supplementary Figure S4) A 4.6 mm250 mm Alltima HP C18 column (5 μm in particle size, Hichrom) was used for the 5 enrichment of CNs and their analogs from the enzymatic digestion products of RNA. A solution 6
of 10 mM dibutylammonium acetate (DBAA) in 5% ACN-95% H2O (solution A) and 10 mM 7 DBAA in 84% ACN-16% H2O (solution B) were used as mobile phases, and the flow rate was 8 0.8 mL/min. A gradient of 20 min 0% B and 40 min 0-40% B was employed. A typical HPLC 9
trace is depicted in Figure 1C . The HPLC fractions eluting approximately at 10. 0-12.0,13.5-15.9, 10 19.0-20.6, 23.0-28.0, 32.0-36.0, 36.0-37.5, 37.5-39.0, 39.0-41.5, 41.5-43.0, and 43.0-46.5 min 11 were pooled for NAD, m 7 Gpppm 1 A, m 7 Gpppm 1 Am, (UDP-Glc and UDP-GlcNAc), (m 7 GpppC, 12 m 7 GpppU, m 7 GpppG and m 7 GpppCm), (GpppC, GpppU, GpppG, m 7 GpppA and m 7 GpppUm), 13 (GpppA, Gpppm 6 A, m 7 Gpppm 6 A, m 7 GpppGm, m 7 GpppAm, m 2,2,7 GpppG and dpCoA), (FAD, 14 GpppCm and m 7 Gpppm 6 Am) and (GpppUm, GpppAm, GpppGm and Gpppm 6 Am), respectively. 15
The collected fractions were dried in the Speed-vac, reconstituted in acetonitrile:water 3:7 (v/v) 16
and dried for three cycles to remove the ion-paring reagent present in the fractions, 17 reconstituted in 8 mM ammonium bicarbonate pH 7.0 (solution C), and injected for LC-MS/MS 18 analysis. 19 20
LC-MS/MS analysis of cap nucleotides 21
Using purchased and synthetic standards, we defined the HPLC retention times for the 26 CNs 22 and two analogs of them (m 7 Gpppm 1 A and m 7 Gpppm 1 Am) on a Luna Omega PS C18 column 23 (100  2.1 mm, 1.6 µm) coupled to an Agilent 1290 HPLC system and an Agilent 6460 triple 24 quad mass spectrometer. The elution was conducted at 15 o C and a flow rate of 200 µL/min, 25 with a gradient of 100% solution C and 0% solution D (methanol) for 5 min, followed by 0% to 1 48% solution D over a period of 12 min. The HPLC column was coupled to an Agilent 6460 2
Triple Quad mass spectrometer with an electrospray ionization source in positive or negative 3 mode with the following parameters: gas temperature, 350 o C; gas flow, 11 L/min; nebulizer, 20 4 psi; sheath gas temperature, 300 o C; sheath gas flow, 12 L/min; capillary voltage, 1,800 V; Am, positive, 10.8, 815, 150 (76 V), 820, 150 26 (76 V); dpCoA, positive, 11.7, 689, 261 (24 V) , 348 (20 V), 136 (40 V); m 2,2,7 GpppG, positive, 1 8. 5, 831, 194 (64 V) , 248 (28 V), 566 (32 V); m 7 Gpppm 1 A, positive, 4.2, 401, 166 (16 V) , 150 2 (36 V); m 7 Gpppm 1 Am, positive, 9.3, 408, 166 (16 V) , 150 (32 V), 111 (36 V). 3 4
Genome-wide nucleotide distribution of TSS 5
To cross-validate the CapQuant results obtained in this study, transcriptional start site (TSS) 6 nucleotide identities were mined from the 5' terminal positions of capped transcripts mapped 7 using cap-analysis gene expression (CAGE) approach (26, 27) . CAGE datasets were chosen 8 over others, such as serial analysis of gene expression, as the CAGE method captures mRNA 9 transcripts at the 7-methylguanosine cap to pulldown the 5'-cDNAs reversely transcribed from 10 them (28) for subsequent tagging and high-throughput sequencing. It achieves genome-wide uploaded into the main public Galaxy server (32) into separate history list with the referent 20 genome set to the latest assembly for further processing. First, non-robust TSS signals were 21 removed in yeast data (c4 of .bedgraph file), a score of >1 and <-1 was Filtered for the positive 22 and negative strand respectively. Second, GetFastaBed under BedTools (33) was used to 23 extract the respective TSS nucleotide information in tab-delimited format and force 24 strandedness applied to reverse complement negative sense strand. GetFastaBed for human 25 and mouse data were obtained from thickStart and thickEnd (c7 and c8) positions, Trimmed up 26 to position 1 to obtain the 5' terminal nucleotide only, Change Case to upper case. Third, Count 1 under Statistics to obtain the TSS nucleotide distribution histograms for human 2 (Supplementary Figure S6b) , mouse (Supplementary Figure S6c) . and yeast data 3 (Supplementary Figure S6d) . As the number of transcripts generated from different TSSs can 4 be very different, the weighted and unweighted nucleotide frequency of TSS could affect 5 correlation accuracy. To account for the weight of TSS usage frequency according to transcript 6 abundance, Datamash was performed by grouping the nucleotides together and summing the 7 CTSS read counts (c5 of.bed file) to obtain the weighted values for human (Supplementary 8 Figure S6b ), mouse (Supplementary Figure S6c ) and yeast (Supplementary Figure S6d) . 9
The work histories can be accessed via https://usegalaxy.org/histories/list_published?f-10 username=alvin_chew 11 12
Dimroth rearrangement 13
Due to the limited quantities of m 7 Gpppm 1 A and m 7 Gpppm 1 Am we obtained, we performed the 14 testing of the Dimroth rearrangement with purchased m 1 A and synthetic m 1 Am nucleoside 15 standards (Supplementary Figure S7) . Because the CCRF-SB mRNA samples were the most 16 abundant mammalian mRNA samples we had and they were the only mRNA samples for which 17 no further purification by rRNA depletion was performed, we chose to use the CCRF-SB mRNA 18 samples for the analysis. We treated a mixture of m 1 A and m 1 Am in the same fashion as CCRF-19 SB cells or the isolated RNA as we went through the RNA extraction, purification, cleanup and 20 enzymatic digestion steps (Supplementary Figure S7a) as described above. The m 1 A, m 6 A, 21 m 1 Am and m 6 Am in the samples were separated on a Hypersil GOLD aQ C18 column (100  1 22 mm, 1.9 µm) coupled to an Agilent 1290 HPLC system and an Agilent 6460 triple quad mass 23 spectrometer. The elution was conducted at 24 o C and a flow rate of 100 µL/min, with a gradient 24 of 100% solution E (0.1% formic acid in water) to 89% solution E-11% solution F (0.1% formic 25 acid in acetonitrile) over a period of 11 min, followed by a gradient of 11% to 80% solution F 26 over a period of 3 min. The HPLC column was coupled to an Agilent 6460 Triple Quad mass 1 spectrometer with an electrospray ionization source in positive mode with the following 2 parameters: gas temperature, 300 o C; gas flow, 5 L/min; nebulizer, 45 psi; sheath gas 3 temperature, 200 o C; sheath gas flow, 5 L/min; capillary voltage, 3,500 V; nozzle voltage, 500 V; 4 fragmentor voltage, 110 V; EMV, 800 V. MRM mode was used for detection of product ions 5 derived from the precursor ions for m 1 A, m 6 A, m 1 Am and m 6 Am with the following instrument 6 parameters (retention time in min, precursor ion m/z, product ion m/z, CE): m 1 A, 2.4, 282, 150, 7 15 V; m 6 A, 6.1, 282, 150, 15 V; m 1 Am, 4.5, 296, 150, 15 V; m 6 Am, 7.8, 296, 150, 15 Experiments were performed with three biological and two technical replicates in hard-shell thin 20
wall PCR plates (#HSP9601; Bio-Rad). No template and no reverse transcriptase controls were 21 used to assess primer dimerization and genomic DNA contamination, respectively. Relative 22 gene expression was calculated using a modified comparative method for geometric averaging 23 of two reference genes, Gapdh and Polr2a, for more reliable normalization (34). Data 24 visualization and Student's t-test statistical analysis was performed using Graphpad Prism 25 software (version 8.0). Error bars represent mean ± s.d., and n.s. means not significant. 
Development of CapQuant 4
The workflow for CapQuant ( Figure 1B) uses nuclease P1 (NP1) to hydrolyze RNA to 5 nucleoside monophosphates (NMPs) while sparing di-and tri-phosphate linkages that 6 characterize the NpppN and NppN caps (24, 35) . Following removal of NP1, cap structures and 7 5'-NMPs in the limit digest are resolved by reversed-phase ion-paring HPLC ( Figure 1C) and 8 cap-containing fractions isolated for subsequent LC-MS/MS quantification. Here we targeted 26 9 caps that embraced a variety of known and possible structures: m 7 GpppN, m 7 GpppNm, GpppN, 10
GpppNm (N = C, U, G, A or m 6 A), and NAD, FAD, UDP-Glc, UDP-GlcNAc, m 2, 2, 7 GpppG and 11 dpCoA. The 26 caps were well resolved from 5'-NMPs (Figure 1C) transitions for the other 6 caps (Figure 1D and E, Supplementary Figure S8 ). This resulted in 5 limits of detection (LODs) ranging from 19 amol to 13 fmol for 23 caps, and up to 160 fmol for 3 6 caps (GpppC, GpppCm and GpppGm; Supplementary Table S1 ). As shown in Figure 1D and 7 E, which depicts applications of the method to mouse (C57BL/6) kidney mRNA and Escherichia 8 coli DH5 total RNA, CapQuant proved to be sensitive, precise, and accurate. 9
Using this new method, control experiments were performed to ensure complete cap release 10 and stability during sample processing. To confirm that all detected caps were indeed covalently 11 linked to mRNA prior to NP1 digestion and not present as contaminants, we used the method to 12 analyze S. cerevisiae mRNA and E. coli total RNA except that NP1 was removed from its stock (Supplementary Figure S10) . Finally, the stability of cap structures 19 during NP1 digestion was verified by spiking cap standards into the RNA digestion reactions 20 with subsequent HPLC purification and isotope-dilution LC-MS/MS analysis (Figure 1D and E) . 21
Recently a new type of mRNA cap has been proposed containing m 1 A (36-38). These caps, 22 m 7 Gpppm 1 A or m 7 Gpppm 1 Am, were predicted based on the binding of m 1 A antibodies to 5' 23 ends of mRNA (39). However, no biochemical validation was presented. To quantify these caps 24 biochemically, we first wanted to develop cap purification protocols that would preserve m 1 A, 1 due to the potential for this nucleotide to convert to m 6 A by the Dimroth rearrangement 2 Figure S7a) (36) (37) (38) , we defined the fate of m 1 A and m 1 Am ribonucleosides 3 during the RNA isolation and processing. As shown in Supplementary Figure S7b , conversion 4 of m 1 A to m 6 A occurred at each step -TRIzol RNA extraction (7%), polyA-tailed RNA 5 purification (17%), GeneRead rRNA depletion (36%), and RNeasy MinElute Cleanup (72%). 6
(Supplementary
This means that for yeast and mouse RNA, which were processed with all steps, 86% of initial 7 m 1 A would have been converted to m 6 A. With LODs of 0.68 fmol for m 7 Gpppm 1 A and 0.11 fmol 8 for m 7 Gpppm 1 Am ( Supplementary Table S1 ), m 1 A-and m 1 Am-containing caps present at 10 9 fmol per g of RNA, which is the lowest level among all of the canonical caps in humans, mice, 10 and yeast as discussed shortly, would remain detectable even with 90% loss. For human RNA, 11
which was processed without rRNA depletion and the RNA cleanup steps, m 1 A and m 1 Am 12 losses were at most 23%, so m 7 Gpppm 1 A and m 7 Gpppm 1 Am should be readily detectable in 13 human mRNA if present. 14 Based on our validation steps, CapQuant was now applied to viral, bacterial, yeast, mouse, and 15 human RNA to discover new cap structures, quantify m 1 A or m 1 Am in caps, and to define the 16 composition and dynamics of the cap epitranscriptome. 17
Quantitative analysis of the cap landscape in eukaryotic, prokaryotic, and viral RNA 18
With an optimized CapQuant method in hand, we applied it to define the landscape of caps in 19 coding and non-coding RNAs from a range of organisms, including humans, mice, yeast, 20 bacteria, and an RNA virus. Focusing first on poly(A)-tailed RNAs (mainly mRNA) from log-21 growing human CCRF-SB lymphoblasts (Figure 2A) , we were able to quantify the components 22 of the cap epitranscriptome. Of the 26 targeted caps, 10 were reproducibly detected for a total 23 of 2,078 fmol of caps per g of RNA. As expected, the five cap 1 structures (m 7 GpppNm) 24 20 comprised the majority of all caps (88%, 1,830 fmol/g RNA) with no cap 0 structures 1 (m 7 GpppN) detected. Consistent with the fact that very few transcriptional start sites (TSS) in 2 humans start with a uridine (Figure 3A and Supplementary Figure S6b ), m 7 GpppUm 3 comprised only 1% of second-nucleotide subtypes (Figure 2A) , which ranged from 23 to 595 4 fmol/g RNA. The most abundant caps were the C, G and A subtypes, found in nearly equal 5
proportions: 33% m 7 GpppCm, 32% m 7 GpppGm, and 19% m 7 Gpppm 6 Am/15% m 7 GpppAm. This 6 distribution correlates strongly with the distribution of predicted TSS (+1 position) frequencies in 7 humans (Figure 3A and Supplementary Figure S6b ). Our analysis further revealed four 8 previously undescribed cap structures (Figure 1A) : m 7 Gpppm 6 A, FAD, UDP-Glc, and UDP-9
GlcNAc. The m 7 Gpppm 6 A structure proved to be relatively abundant at 12% of all mRNA caps 10 (244 fmol/g RNA), which contradicts previous claims of the absence of this cap based on crude 11 thin-layer chromatography analyses (14) and in a non-quantitative LC-MS assay (18) . 12
Additionally, this cap demonstrates that 2'-O-methylation is not essential in mRNAs, as has 13 been previously suggested to suppress innate host antiviral responses (3). The structures of the 14 four metabolite caps (NAD, FAD, UDP-Glc and UDP-GlcNAc) were unequivocally confirmed by 15 three signature MRM transitions defined with standards (Figure 1E and Supplementary Figure  16 S8). Compared to cap 1 structures, however, the levels of these metabolite caps were ~100-fold 17 lower at 0.40-2.9 fmol/g RNA (Figure 2A and Table 1 ). UDP-GlcNAc and NAD being the two 18 most abundant structures is consistent with the relative abundance of these metabolites in 19 human cells (40,41) and thus with the idea that nucleotide metabolites can initiate transcription 20 (9) . Notably, we were unable to detect m 7 Gpppm 1 A or m 7 Gpppm 1 Am in human mRNAs 21 Figure S11) . 22
(Supplementary
We next sought to understand whether the cap epitranscriptome is different in different cell 23 types. The same 10 mRNA caps observed in the human cells were also found in mouse liver 24 and kidney tissue mRNAs at 1,131 and 566 fmol/g RNA, respectively. Mice similarly showed 25 relatively low abundance of m 7 GpppUm and high levels of m 7 GpppGm and m 7 GpppCm ( Figure  1 2B and Table 1) , though m 7 GpppAm was >5-fold lower in mice liver and kidney than in human 2 CCRF-SB cells (Figure 2B and Table 1 ). The large differences between the ratio of m 7 GpppAm 3 and m 7 Gpppm 6 Am in different cell types supports a role for m 6 Am as a regulatable modification 4 in mRNA. A comparison of caps in liver and kidney showed several striking tissue-specific 5 differences, most notably the absence of detectable m 7 Gpppm 6 A in kidney (Figure 2B and 6 Table 1 ). Other tissue-specific differences include >2-fold lower levels of m 7 GpppGm (p > 0.05), 7 m 7 GpppAm (p > 0.05), m 7 Gpppm 6 Am (p < 0.05), and UDP-Glc (p < 0.01) in kidney compared to 8 liver, and small variations in the levels of m 7 GpppCm, m 7 GpppUm, NAD, FAD and UDP-GlcNAc 9 (Figure 2B) . Similar to humans, the cap second nucleotide distribution correlates strongly with 10 the distribution of predicted TSS frequencies in mice (Figure 3B and Supplementary Figure  11 S6c). 12
In contrast to the cap 1 structures in mammalian cells, the only canonical caps in S. cerevisiae 13 were the expected cap 0 structures (m 7 GpppN), with abundances between 20 and 1,524 14 fmol/g RNA (Figure 2C and Table 1 ). m 7 GpppA constituted 80% of all caps (1,896 fmol/g), 15 with m 7 GpppA > m 7 GpppG (16%) >> m 7 GpppU (1.5%) > m 7 GpppC (1.1%). This distribution 16 correlates strongly with the distribution of predicted TSS frequencies in S. cerevisiae (Figure 3C  17 and Supplementary Figure S6d) . The four nucleotide metabolite caps were present in the S. 18 cerevisiae mRNAs at abundances from 2.0 to 12.4 fmol/g RNA, which is higher than in 19 humans and mice (Figure 2A-B and Table 1 ). Notably, we found no evidence for the presence 20 of methylated forms of A in any cap structures in yeast. 21
The tissue-specific variations in cap structure and quantity in mice raised the possibility that cap 22 landscape would vary as a result of stress-specific changes in gene expression. To this idea, we 23 quantified the cap profile in yeast exposed to well-characterized oxidative and alkylation 24 stresses caused by hydrogen peroxide (H2O2) and methyl methanesulfonate (MMS), 1
respectively. Both treatments resulted in modest changes in the levels of several caps (Figure  2 2C), with a significant increase in the level of UDP-GlcNAc cap (p < 0.01). However, there were 3 no striking changes in cap levels for these two stressors. 4
As expected, the m 7 G-type cap structures typical of eukaryotes were not detectable in the total 5
RNA from E. coli (Figure 2D and Table 1 ). Here we analyzed total RNA instead of mRNA 6 because of the low prevalence of polyA tails in the E. coli mRNA pool, with only 2-50% of 7 mRNAs shown to have polyA that are generally short at 14-60 nt (42). While NAD and UDP-8
GlcNAc were the major metabolite caps, which is consistent with the relatively high 9 concentration of these metabolites in E. coli (43), the four metabolite caps in E. coli occurred at 10 10-fold lower levels than in yeast, ranging from 0.20 to 2.5 fmol/g RNA (Figure 2D and Table  11 1). This suggests differing propensities of the yeast and bacterial RNA polymerases for using 12 nucleotide metabolites to initiate transcription. 13
Finally, in dengue purified virion RNA genomes, the total level of detected caps amounted to 14 325  114 fmol/g RNA. This is consistent with nearly all copies of the ~10,700 nt RNA genome 15 (288 fmol/g RNA) possessing a cap. The major cap structure (70%) was found to be the cap 1 16 m 7 GpppAm at 226 fmol/g RNA (Figure 2E and Table 1) . Surprisingly, the cap 0 structure 17 m 7 GpppA represented 14% of all caps. The abundance of the four metabolite caps ranged from 18 2.5 to 44.8 fmol/g RNA, which is similar to yeast. 19 20
DISCUSSION 21
Here we present CapQuant, an analytical method combining off-line HPLC enrichment with 22 isotope-dilution LC-MS/MS analysis for analysis of the diversity and dynamics of the cap 23 epitranscriptome. This method overcomes the shortcomings of existing cap analysis tools, 1 which are limited to individual cap structures (20, 44, 45) , are poorly quantitative (5, 14, 18) , and 2 lack of chemical specificity (5, 14) , to enable accurate, specific and sensitive quantification of the 3 RNA cap landscape in any organism. It achieves high-coverage with absolute quantificationa 4 key feature of the methodover a broad dynamic range starting at attomole levels (as little as 5 600 ng of RNA) and the capacity to expand to other new RNA cap structures, including the 6 methylated guanosine caps observed in pre-tRNA (21). While isotope-labeled internal standards 7 provide highly accurate absolute quantification, rigorous cap quantification can still be 8 performed with external calibration curves using unlabeled standards or even with other 9
chemically similar cap standards. The use of off-line ion-pairing HPLC (46) The lack of detectable GpppN caps could reflect the cap quality control system described in 1 mammalian (DXO/Dom3Z protein) and yeast cells (Rai1-Rat1 and Dxo1). These systems 2 possess decapping, pyrophosphohydrolase, and 5'-to-3' exonuclease activities that appear to 3 target caps lacking m 7 G (49,50) . 4
With regard to m 1 A, two antibody-based methods concluded that m 1 A was widespread in 5 mammalian mRNA (36, 37) , with subsequent studies proposing that m 1 A could exist as part of a 6 novel cap structure comprising m 7 Gpppm 1 A or m 7 Gpppm 1 Am (39). However, biochemical 7 studies were not used to demonstrate the existence of these novel mRNA caps. Another study 8 used an antibody and sequencing-based approach to detect m 1 A-induced reverse transcriptase 9 errors and suggested that m 1 A was present at much lower levels than previously thought (38) . 10
Here we demonstrate that m 1 A is unlikely to be present at appreciable levels in mRNA caps, as 11 least in cultured human lymphoblasts. Even after quantitatively accounting for artifactual loss of 12 m 1 A by Dimroth rearrangement to m 6 A and optimizing the CapQuant method to minimize this 13 conversion, we did not detect any m 7 GpppN or m 7 GpppNm caps containing m 1 A or m 1 Am. Our 14 data suggest that the levels of m 1 A and m 1 Am at mRNA caps, if they exist, are below the LODs 15 which are 0.68 fmol and 0.11 fmol respectively. Thus, although this study does not rule out the 16 existence of m 1 A//m 1 Am at mRNA caps, they are below the limits of detection, which suggests 17 that they, if present, are found in less than 1/16,000 and 1/100,000 mRNA transcripts 18 respectively from cultured human lymphoblasts. It should be noted that we did not attempt to 19 solve the Dimroth rearrangement problem, thus we cannot be sure about the cap m 1 A//m 1 Am 20 status. However, our observations raise a warning on interpreting any data on m 1 A//m 1 Am in 21
RNA. While previous sequencing-based methods reported about a couple dozens of cap m 1 A in 22
the HEK293T cells (38), the existence of cap m 1 A/m 1 Am in different tissues or samples needs 23 further investigation. 24
In terms of novel cap discovery, we detected m 7 Gpppm 6 A as a novel cap in mRNA from human 1 cells and mouse liver (Figure 2A-B and Table 1) . The presence of m 7 Gpppm 6 A in mouse liver 2 but not kidney points to a tissue-specific role for this cap. This could arise by demethylation of 3 the m 7 Gpppm 6 Am cap through a yet unknown demethylase, or by N 6 -methylation of adenosine 4 at the first transcribed nucleotide in mRNAs independent of the adenosine 2'-O-methylation 5 status. Indeed, recent in vitro biochemical studies have shown that PCIF1, the enzyme 6 responsible for synthesis of m 6 Am in mRNA caps, can also act on m 7 GpppA-capped mRNA to 7 form m 7 Gpppm 6 A-capped mRNA (18, 51, 52) . Thus, in cells, m 7 GpppA caps might undergo either 8 2'-O-methylation, N 6 -methylation, or both. 9
CapQuant also expanded the repertoire of 5' cap structures with the discovery of three novel 10 metabolite caps (FAD, UDP-Glc and UDP-GlcNAc) in all the RNA species analyzed (Figures 1  11   and 2) . This expands the generality of the idea that nucleotide metabolites can serve as caps in 12 cellular and viral RNA (2) . However, metabolite caps (NAD, FAD, UDP-Glc and UDP-GlcNAc) 13 are rare in eukaryotes, accounting for 0.3-5.1% in total of all caps detected (Figure 2 and Table  14 1) across eukaryotic cells and tissues. There is a strong stochastic basis for metabolite caps 15 formation due to (i) their low abundance relative to the NpppN canonical caps in eukaryotes 16 (>10-fold lower; 0.2-20 fmol/g versus 10-600 fmol/g), (ii) the similar frequencies of each cap 17 type in all organisms, (iii) the variation in metabolite cap levels among tissues and stresses, and 18
(iv) their proportionality to cellular metabolite pools. The role of nutrient availability and 19 metabolite pools as determinants of metabolite cap levels is illustrated by several studies. First, 20 it was shown by Walters et al. (53) that there were more NAD-capped mRNAs in S. cerevisiae 21 grown in minimal medium compared to rich YEPD medium, which suggests that the levels of 22 NAD caps are sensitive to nutrient status. Similarly, Canelas et al. found that NAD levels in S. 23 cerevisiae are sensitive to culturing conditions and nutrient status (54). This variability in 24 metabolite levels as a determinant of metabolite cap levels may explain the 33-fold difference in 25 NAD caps observed here and in the studies of , 1 though contributions from the different analytical methods could also account for the different 2 NAD cap levels. Finally, Grudzien-Nagolska et al. demonstrated that changes in cellular NAD 3 levels in HEK293T cells correlate with changes of the levels of NAD caps (45). These studies all 4
show a variability in metabolite cap levels based on metabolite pool levels in a way that 5 suggests a potential signaling or regulatory function of metabolite caps. An emerging literature 6 supports this idea. For example, the NAD cap has been shown to be present on a subset of 7 mRNAs that are targeted for rapid decay in mammalian cells (11,55), while Kiledjian and 8 coworkers have observed a post-transcriptional NAD capping activity, which suggests that this 9 cap is not simply a transcriptional mistake (11). 10
The potential for variation in metabolite cap levels as a function of cell state is also illustrated 11 with viral infections. For example, human cytomegalovirus (HCMV) infection upregulates UDP-12
GlcNAc levels in host cells (56) with similar metabolic shifts observed in other viruses (57, 58) . 13
Hence it is proposed that dengue infection upregulates host cellular UDP-GlcNAc levels, 14 especially since viral envelope (E) protein N-glycosylation is partly derived from UDP-GlcNAc in 15 host cells (59,60). Higher host cell levels of UDP-GlcNAc may lead to increased transcription 16 initiation with this nucleotide metabolite, which would explain the relatively large proportion of 17 UDP-GlcNAc-capped viral transcripts detected in dengue purified virions (Figure 2E and Table  18 1). While the biological function of these metabolite caps requires further examination, RNA 19
Pols appear to be capable of initiating transcription with the four nucleotide metabolites studied 20 here and that dengue virus NS5 polymerase could initiate transcription with the metabolite caps 21 in the same manner as the host RNA Pol. However, the ability of the metabolite-capped viral 22 genomes to sustain viral replication is unknown. In addition to the above question regarding 23 biological function, the discovery of the three novel metabolite caps also raises several other 24 important questions. For example, can metabolite caps be exported from the nucleus into the 25 cytoplasm in eukaryotic cells? Are metabolite caps found in RNAs that associate with 1 polysomes? We think that answers to these questions can be readily obtained by directly 2 applying CapQuant to relevant systems, i.e., RNA preparations from the nucleus and cytoplasm 3 from the same population of cells, and polysome-bound RNAs. 4
Consistent with published observations, we found that the cap on the dengue RNA genome 5 isolated from purified virions contained Am but not m 6 Am (Figure 2E and Table 1 ) as compared 6
with human mRNA (12, 61) . CapQuant revealed that >30% of the viral particles generated 7 during an infection possess caps that are counterproductive for viral replication and survival in 8 the host: presumably untranslatable metabolite caps or the m 7 GpppA cap that activates innate 9 immunity (Figure 2E) . With an estimated single copy of the RNA genome per viral particle (62) 10 and one viral particle infecting a host cell, the varying viral cap structures detected suggest that 11 infections will occur with viral genomes having different translational efficiency or propensity to 12 activate the antiviral response pathways. The fate of these variously capped viral genomes in 13 the host is largely known. Indeed, there is controversy concerning the presence of m 6 Am in the 14 caps on dengue-derived mRNAs isolated from infected cells, which presumably arise by 15 replication of the infective genomic RNA (12, 61, 63) . The sole published experimental work 16 showed that only Am is found in dengue mRNA caps (63). The variable detection of m 6 Am in 17 dengue mRNA caps could be explained by contamination with the abundance of host mRNA 18 containing m 6 Am (Figure 2A and Table 1 ) or by N 6 -methylation of viral genomes and/or mRNA 19 by host enzymes PCIF1 (18, 51, 52) . Our observation that dengue genomic RNA present in 20 purified virions lacks m 6 Am in the cap implies that any N 6 -methylation of Am in caps, if required 21 for translation, must occur in viral transcripts used for protein production. However, replicated 22
RNA genomes destined for virion assemblies can only possess m 7 GpppAm, m 7 GpppA, and the 23 metabolite caps, as we observed (Figure 2E and Table 1 ). While some studies suggest that 24 cap m 6 Am stabilizes a subset of mRNAs (24), other studies did not observe this effect 25 28 (18, 64, 65) . Interestingly, N 6 -methylation of A within the viral mRNA has been found to negatively 1 regulate viral infection by reducing viral particle formation (66), while we have previously 2 demonstrated that Am is present throughout the RNA genome of purified dengue virions (23) . 3
Clearly, there is significant work to be done to clarify the capping mechanisms involved in the 4 various steps of viral infection. 5
CapQuant also showed that 14% of dengue genomes possess m 7 GpppA cap, and that 12% of 6 human and 3% of mouse liver mRNAs possess m 7 Gpppm 6 A caps (Figure 2 and Table 1) . 7
Although the observation of the latter stands in contrast to the inability to detect it in a crude, 8 chemically-non-specific TLC method (5) or in insensitive LC-MS studies lacking standards (18), 9
the detection of m 7 Gpppm 6 A caps is rigorously established here based on chromatographic and 10 structural identity with a synthetic standard. The presence of m 7 Gpppm 6 A caps in human and 11 mouse liver mRNAs is unlikely due to inefficient cellular 2'-O-methyltransferase activities or 12 insufficient cellular innate immunity targeting cap 0 structures (67) since none of the other cap 0 13 structures were detectable in these RNAs, even in human CCRF-SB mRNA where the levels of 14 m 7 GpppCm, m 7 GpppGm and m 7 GpppAm were almost twice or comparable to the level of 15 m 7 Gpppm 6 Am (Figure 2 and Table 1 ). Thus, these data suggest that at least in some cell types 16 2'-O-methylation is not present in all mRNAs, potentially suggesting that there may be specific 17 cellular contexts in which 2'-O-methylation is not needed to suppress the innate host antiviral 18 response (3). It is well established that RIG-I and MDA5 are sensors of non-self RNA in 19 mammalian cells, and the IFIT complex is a dual sensor-effector of a cellular innate defense present during a dengue infection correlate with virulence? It is reasonable to hypothesize that 1 the more virulent dengue strains have evolved to minimize the proportion of m 7 GpppA caps that 2 activate the innate antiviral response in host cells, a hypothesis readily tested by application of 3 CapQuant to clinical dengue isolates replicated in culture. It is worth noting that previous efforts 4 using two-dimensional TLC-or LC-MS-based methods did not detect m 7 Gpppm 6 A cap in mRNA 5 from human cells (5, 18) . Although it is possible that m 7 Gpppm 6 A cap was indeed absent in 6 those RNA preparations, the failure to detect this cap could also be due to lack of chemical 7 specificity and insufficient sensitivity of the two-dimensional TLC method (5) or due to lack of 8 sensitivity and selected monitoring of m 7 G-capped dimers (m 7 GpppN1Gp) to pentamers 9 (m 7 GpppN1N2N3N4Gp) containing 0-3 methyl groups, which include only a portion of all possible 10 m 7 G-capped sequences with A or methylated A as the first transcribed nucleotide, in the LC-MS 11 method (18) . Interestingly, the level of m 7 Gpppm 6 A cap in mRNA differed significantly among 12 human CCRF-SB, mouse liver and mouse kidney (Figure 2A-B) . To explore if these differences 13 is linked to possible differences in expression of relevant cap modification enzymes, we 14 assessed the relative expression of a selection of RNA cap modification enzymes including 15 PCIF1, FTO, DCP2 and CMTR1 as well as ALKBH5 in the total RNA from CCRF-SB cells and 16 mouse liver and kidney tissues on the transcription level by RT-qPCR. We observed no 17 statistically significant difference between any two of these three samples in the relative 18 expression of any enzyme examined (Supplementary Figure S12) , suggesting that the 19 differences in the level of m 7 Gpppm 6 A cap are likely due to other factors. We speculate that two 20 such factors are secondary structure of 5' ends of mRNAs (69) and helicase activity that is 21 critical for CMTR1-mediated 2'-O-methylation of cap 1 in mRNAs harboring highly structured 5' 22 ends (70) . Further studies are needed to fully address this question. 23
CapQuant analysis also provided strong corroboration for TSS studies, which are challenging 24 due to the lack of long and conserved consensus sequences for TSSs. m 7 G caps with a purine 25 as the first transcribed nucleotide represented the major caps found in mRNAs from human 1 CCRF-SB (70%), mouse liver (82%) and kidney (74%) tissues, and S. cerevisiae W1588-4C 2 (97%), with the relative abundance of different m 7 GpppNm's or m 7 GpppN's varying across the 3 organisms and tissues (Figure 2A-C and Table 1 ). This preference for purines at the 4 penultimate position in m 7 GpppN caps is rationalized by the strong preference for pyrimidine-5 purine dinucleotides at -1 and +1 positions of TSSs in the coding strand of eukaryotes, bacteria 6 and some viruses, which is argued to facilitate the loading of ATP or GTP during transcription 7 initiation (72-74). A comparison of the distribution of the second nucleotide in 8 m 7 GpppN/m 7 GpppNm caps revealed by CapQuant to the distribution of TSSs (+1 position) 9 predicted using the cap analysis gene expression (CAGE) method (29,75) was conducted for 10 cross-validation. The CAGE method is advantageous over other TSS analysis methods in that it 11 only captures capped transcripts and thus avoids false TSSs from degraded transcripts that do 12 not contain caps. We observed a strong correlation between the cap second nucleotide 13 distribution and the TSS distribution for S. cerevisiae, mice and humans (Figure 3A-C and  14 Supplementary Figure S6b-d) . 15
CapQuant is not without limitations. For example, the level of all caps per g of mRNA in the 16 mouse tissues was about 2-to 4-fold lower than in human cells and yeast. ( Table 1) . We cannot 17 explain it, but could be due to presence of other types of caps not quantified in the present 18 studies or a higher proportion of uncapped RNAs in the mouse tissue mRNA preparations. It is 19 unlikely due to rRNA contamination as the Bioanalyzer profiles of all the cell and tissue mRNA 20 preparations indicated undetectable level of rRNA contamination (Supplementary Figure S4) . 21
Also, it should be noted that in human, S. cerevisiae and E. coli cells, the levels of NAD cap 22 revealed in the present study ( Table 1 ) are up to 55-fold lower than those levels of the same 23 cap determined or estimated in other studies (20, 45) . In addition to the variable accuracy of the 24 different analytical methods, lower levels of NAD detection in the present studies could be due, 25 at least in part, to differences in the cell culture conditions (45, 53, 54) and cell strains used in the 1 different studies, as discussed earlier. In the case of E. coli, we analyzed caps in stationary-2 phase cells whereas Chen et al. analyzed caps in log-phase E. coli (20) , which could contribute 3 to the lower NAD cap level observed in our study. In addition, the non-significant changes in the 4 abundance of NAD in the control experiments by Chen et al. (20) when spiking large amounts of 5 NAD into the cell lysate prior to RNA isolation cannot rule out the possibility that the NAD they 6 detected in the samples represented contaminating non-covalently bound NAD. CapQuant 7 employs isotopically-labeled internal standards for cap quantification, which enhances the 8 accuracy of the method. 9
In summary, beyond the applications in the quantification of cap structures in any type of RNA 10 from in vivo or in vitro sources, CapQuant has wide potential use in many biological fields. 11
Primarily, it can facilitate investigations into the dynamics, function and regulation of RNA caps 12 in a broad wide range of biological processes and conditions. In addition, it can be readily 13 applied to study RNA metabolism, such as RNA capping, RNA decapping and RNA decay. 14 Notably, when combined with transcript-specific purification technology (76), it enables 15 quantification of cap structures in specific transcripts and thus studies of transcript-specific 16 capping and decapping, and gene-specific regulation. Finally, it permits investigations into the 17 roles that cap-binding proteins, such as eIF4E and CBC, may play in the control of gene 18 expression (77). 19 20
SUPPLEMENTARY DATA 21
Supplementary Data are available online. 22 Values represent mean ± SD for three independent cultures for CCRF-SB, W1588-4C and 16 DH5, for three biological replicates of three mice and H2O2-or MMS-treated W1588-4C cells, 17 and for three technical replicates of a single culture for DENV-2. 18 
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